Assessment of Dosimetric Accuracy and Plan Quality in Prostate SBRT: Retrospective Evaluation of 36.25 Gy in 5 Fractions Using RapidArc on Varian Millennium MLC with MLC Parameter Analysis

Ajithkumar M

Department of Radiotherapy, Meherbai Tata Memorial Hospital, Jamshedpur, India

makumar735@gmail.com

Subhankar Show

Department of Radiotherapy, Meherbai Tata Memorial Hospital, Jamshedpur, India

subhankarshow003@gmail.com

Aaditya Prakash

Department of Radiotherapy, Tata Main Hospital, Jamshedpur, India

aaditya.prakash@tatasteel.com

Abstract

Introduction

Prostate cancer is one of the most commonly diagnosed cancers among men worldwide. Advances in radiotherapy, particularly Stereotactic Body Radiotherapy (SBRT), have enabled ultra-hypofractionated treatment schedules that enhance tumor control while reducing treatment time. This study focuses on evaluating the dosimetric accuracy and plan quality of prostate SBRT using RapidArc technology on a Varian Millennium Multileaf Collimator (MLC) system.

Objectives

To retrospectively evaluate the dosimetric parameters, plan quality metrics, and multileaf collimator performance in prostate SBRT delivered via RapidArc, and to assess target coverage, organ-at-risk (OAR) constraints, and delivery efficiency.

Materials and Methods

A total of 24 patients with localized prostate adenocarcinoma received SBRT with a prescribed dose of 36.25 Gy in five fractions. Treatment planning was performed using Eclipse v15.6 with Acuros XB algorithm, utilizing three 6 MV flattening filter-free (FFF) arcs. Planning Target Volume (PTV) coverage, OAR doses, Paddick Conformity Index (PCI), Gradient Index (GI), and Monitor Units (MU) were analyzed. Multileaf collimator motion was evaluated through log files, including leaf speed and

position dynamics. Quality assurance was performed using electronic portal imaging devices (EPID) and gamma pass rate evaluation.

Results

The mean PTV D_{95} was 35.80 ± 0.46 Gy, with mean Dmax and Dmean being 39.80 ± 1.05 Gy and 37.10 ± 0.40 Gy, respectively. $V_{95\%}$ averaged 99.13 ± 1.14%, confirming adequate coverage. Slight violations of rectum and bladder Dmax constraints were observed but remained clinically acceptable. The mean PCI and GI were 0.905 ± 0.18 and 3.08 ± 0.16, respectively. Gamma pass rates exceeded 99.6% for 2%/2 mm criteria. MLC leaf speed remained below the 3 cm/s threshold, ensuring mechanical safety and dose delivery accuracy.

Conclusion

Prostate SBRT delivered via RapidArc on a Varian Millennium MLC system demonstrated high plan conformity, efficient delivery, and acceptable OAR sparing. The integration of intra-fraction CBCT improved setup accuracy, while MLC analysis confirmed mechanical precision. This approach supports the clinical adoption of RapidArc-based SBRT as a feasible and effective option for localized prostate cancer treatment.

Keywords:

Stereotactic Body Radiotherapy, Prostate Cancer, Radiotherapy Planning, Organs at Risk, Dose Distribution, Volumetric Modulated Arc Therapy, Multileaf Collimator

Introduction

Prostate cancer remains an important global health challenge, particularly affecting aging male populations worldwide. Advances in radiotherapy have revolutionized its management, with technological innovations enabling precise targeting and dose escalation to improve tumor control while minimizing adverse effects. Among these developments,(SBRT) has emerged as a promising treatment modality, delivering high biological doses in five fractions, thus offering a more convenient and resource-efficient alternative to conventional radiotherapy regimens[1,2].The radiobiological rationale for hypofractionation in prostate cancer is grounded in its low alpha/beta ratio (~1.5 Gy)[1-10], which suggests that larger doses per fraction can enhance tumor control and potentially spare normal tissues. Supporting this approach, clinical trials such as PACE-B and HYPO-RT-PC have demonstrated favorable outcomes with regimens like 36.25 Gy in five fractions, showing good tolerability and promising efficacy[3]. These findings align with the trend toward ultra

hypofractionation, which aims to optimize treatment efficacy while reducing treatment duration, healthcare costs, and patient burden.

However, the success of such high-dose, few-fraction treatments hinges critically on meticulous dosimetric planning. Precise delineation of target volumes and organs at risk (OARs)—notably the bladder, rectum, and testes—is essential to maximize tumor coverage and minimize radiation exposure to surrounding normal tissues. Particular attention must be paid to protecting the testes to prevent unintended gonadal irradiation, which can lead to hormonal disturbances such as hypogonadism. Techniques like advanced image-guided planning and the use of shielding are vital in achieving these goals[1-3].

Given the ongoing evolution of prostate radiotherapy protocols and the increasing adoption of SBRT, our study aims to evaluate the plan quality and adherence to dose constraints in delivering prostate SBRT in five fractions. This research will contribute to establishing standardized dosimetric guidelines, ensuring safe and effective treatment while preserving the quality of life for patients. As the landscape of prostate cancer treatment continues to advance, precise and validated dosimetric planning remains the cornerstone for translating promising clinical outcomes into routine practice.

Objectives:

The objective of this study was to retrospectively evaluate the dosimetric accuracy, plan quality, and MLC performance in the delivery of prostate SBRT using the RapidArc technique on a Varian Millennium MLC system. The study aimed to assess target coverage,OAR dose constraints, plan conformity, and delivery efficiency,including MLC leaf dynamics and QA metrics based on treatment data from 24 patients treated with 36.25 Gy in five fractions.

Materials and Methods

Study Design and Patient Selection:

This retrospective cohort study included a total of 24 patients diagnosed with localized prostate cancer between [2022–2025] .The sample size was based on all eligible non-metastatic cases treated during the study period. Diagnosis was established using serum prostate-specific antigen (PSA) testing, digital rectal examination (DRE), transrectal ultrasound-guided biopsy, and computed tomography (CT) imaging to confirm localized disease. All patients received SBRT in

exactly five fractions, following established ultra-hypofractionation protocols for prostate cancer.

Inclusion Criteria:-

1.Male patients aged 18 years or older,
2.Histologically confirmed prostate adenocarcinoma,
3.Clinical staging indicating localized disease (e.g., T1c-T3a),
4. No evidence of metastatic disease,
5.Prostate volume within the range suitable for SBRT (e.g., 90-120 cc),
6.Adequate organ function and performance status suitable for radiotherapy.

Exclusion Criteria:-

1.Prior pelvic radiotherapy,
2.Significant comorbidities contraindicating SBRT,
3.Presence of metastatic or locally advanced disease beyond T3a,
4.Inability to tolerate immobilization or imaging procedures necessary for SBRT.

Expected Outcomes:

High Target Coverage and Conformity: The treatment plans are expected to achieve ≥95% coverage of the PTV with the prescribed dose, along with excellent conformity indices, ensuring effective tumor control.

OAR Sparing: Dose constraints for critical structures such as the rectum, bladder, penile bulb, and femoral heads are anticipated to remain within or close to accepted tolerance levels, thereby minimizing toxicity.

Dosimetric Precision and Delivery Accuracy: High gamma pass rates (>99%) and consistent MLC performance are expected, reflecting accurate dose delivery and high treatment fidelity.

Treatment Delivery Efficiency: Rapid treatment times (~70–90 seconds per arc) and the integration of intra-fraction CBCT imaging are anticipated to facilitate efficient treatment delivery and precise patient positioning.

Feasibility and Safety of Hypofractionation: Delivering 36.25 Gy in five fractions is expected to be dosimetrically feasible, with acceptable heterogeneity and controlled OAR doses, supporting its safe clinical application.

Imaging and Target Volume Delineation

All patients underwent CT simulation with a 1_mm slice thickness using a linear accelerator. Immobilization was performed in the supine position with knee and foot supports. Patients followed bladder filling and rectal emptying protocols to reduce internal organ motion. CT images were imported into the Eclipse 15.6 treatment planning system (Varian Medical Systems, Palo Alto, CA, USA)[1].

The gross tumor volume (GTV) was delineated based on Magnetic Resonance Imaging(MRI) and PET/CT imaging, particularly utilizing ^{18}F-FDG PET scans to identify recurrent or dominant tumor sites. The clinical target volume (CTV) included the prostate and seminal vesicles, with an isotropic 3 mm margin applied to account for microscopic spread. The planning target volume (PTV) was generated by adding a maximum 3 mm isotropic margin around the CTV to accommodate setup uncertainties, ensuring precise targeting.

Organs at risk (OARs), such as the bladder, rectum, penile bulb, femoral heads, and small bowel, were contoured following standard guidelines. The rectum extended from the ischial tuberosities to the rectosigmoid flexure; the bladder encompassed the entire organ. Additional OARs, including the penile bulb and femoral heads, were contoured for dose monitoring.

Treatment Planning and Delivery

Treatment plans were developed in Eclipse 15.6 (Varian Medical Systems, Palo Alto, CA, USA) using the Acuros XB(AXB) algorithm for dose calculation. The prescribed dose was 36.25 Gy delivered in five fractions. Plans aimed for at least 95% of the PTV volume to receive the prescribed dose ($V_{95} \geq 95\%$), with the isodose line set at 95% to cover the target, allowing hotspots up to approximately 111% within the PTV.

The optimization utilized three full arcs with 6 FFF photon beams configured as Volumetric Modulated Arc Therapy (VMAT). The plan prioritized conformality and OAR sparing, with the dose distribution normalized to keep the 95% isodose line encompassing the PTV. Hotspots within the target were permitted to reach up to 111% of the prescribed dose, provided they did not exceed OAR constraints. Dose constraints included maximum doses of 40 Gy to the penile bulb and 38 Gy to the rectum and bladder.

DVH analyses evaluated key metrics: D_{95}, Dmax, Dmean, and V_{95} for the target. The primary target coverage metric was V_{95}, representing the percentage volume of the PTV receiving at least 95% of the prescription dose.

Dosimetric Parameters and Plan Quality Metrics

The PCI, a widely used measure of plan conformity[5,9], was calculated as follows:

$$PCI=(TV_{PIV})^2/(TV \cdot PIV)$$

Where:

TV_{PIV}: Target volume covered by prescription isodose volume

TV: Target volume

PIV: Prescription isodose volume

A PCI close to 1 indicates optimal conformity.

Gradient Index (GI)

Defined as:

$$GI = V_{50\%}/VPTV_{95\%}$$

Where $V_{50\%}$ is the volume receiving 50% of the prescription dose. This aligns with the standard used in RTOG protocols for assessing dose fall-off outside the target. A lower GI (Typically 3-4) reflects a steeper dose gradient, indicating better normal tissue sparing.

MLC Parameters

Leaf Width: Typically 5 mm, optimized for precise shaping.

Maximum Leaf Speed: Recorded to ensure MLC movements are within machine capabilities (e.g., 3 cm/sec)[5].

MLC Position Over Time: The MLC leaf positions were logged at 20ms intervals during treatment delivery, allowing analysis of leaf motion patterns, stability, and dynamic adaptation. Mean MLC leaf speed was calculated based on positional changes over time, ensuring consistent and accurate dose delivery (Figures 6, 7).

Treatment Delivery Data

MU Count: Total monitor units delivered per plan.

MLC Motion Patterns: Assessed from logged positional data to evaluate plan complexity(Total MU/cGy) and delivery efficiency.

Treatment Times: Total beam-on time recorded to evaluate treatment efficiency

Quality Assurance and Verification

The advanced irradiation techniques in a radiotherapy clinic require extensive dose verification measures that go beyond current routine clinical practice. Amorphous silicon electronic portal imaging devices (a-Si EPIDs) (e.g., Varian aS1200, Varian Medical Systems, Palo Alto, CA, USA). Pre-treatment verification was performed using the a-Si EPID_(Varian aS1200, Varian Medical Systems, Palo Alto, CA, USA) system, with gamma passing rates evaluated at 3%/2 mm and 2%/2 mm criteria to ensure plan accuracy.

Statistical Analysis

All dosimetric parameters, including D_{95}, Dmax, Dmean, V_{95}, and OAR doses, were statistically analyzed. Descriptive statistics summarized plan quality, and comparisons were made to assess consistency across patients. A significance threshold of $p<0.05$ was applied.

Treatment plans were developed in Eclipse 15.6(Varian Medical Systems, Palo Alto, CA, USA). The plans used three 6 MV FFF arcs, with the isodose line set at 95% to ensure adequate target coverage, allowing hotspots up to 111%[3,5-6]. The approach emphasizes robust tumor coverage ($V_{95} \geq 95\%$) while maintaining strict OAR constraints, aligning with current clinical practices for safe, effective ultra hypofractionated prostate radiotherapy.

Ethics

The procedure followed were in accordance with the ethical standards of the responsible committee on human experimentation and the Helsinki Declaration of 1964,as revised in 2013.The study was approved by the institutional Ethics Committee of Meherbai Tata Memorial Hospital,Jamshedpur(IEC/2025/Jun 23),dated Jun 23,2025 and waiver of consent was obtained as this was retrospective study.

Results

TABLE 1: Patient Demographics

Characteristic	Number/Details
Total Patients	24 Patients
Age (years),mean±SD	50.0±6.7
Age Range	30–70
Gender	Male(24 Patients)
Disease Staging (clinical T-stage)	
–T1c	6 patients(25%)
–T2a	8 patients(33%)
–T2b	5 patients(21%)
–T3a	5 patients(21%)

Table 1: Summary of baseline demographic and clinical characteristics for 24 male patients with localized prostate cancer treated with (SBRT) to a total dose of 36.25 Gy in 5 fractions. Clinical T-stage distribution includes T1c to T3a disease.

A total of 24 patients were included in the study. The demographic characteristics are summarized in Table 1. The mean age was 50.0 ± 6.7 years, with an age range from 30 to 70 years. All patients were male and presented with localized disease at diagnosis.

TABLE 2: Statistical Summary of Dosimetry Metrics

Structure	Metric	Average±SD	Unit	Constraint
PTV	Dmean	37.10±0.40	Gy	-
PTV	Dmax	39.80±1.05	Gy	-
PTV	D_{95}	35.80±0.46	Gy	≥Prescription (36.25 Gy)
PTV	Dmin	32.51±0.52	Gy	-
PTV	$V_{95(\%)}$	99.13±1.14	%	≥95%
Bowel Bag	Dmax	21.55±1.12	Gy	<35Gy
Bowel Bag	V_{20Gy}	25.50±69.45	cc	<50cc
Bladder	Dmax	38.76±0.86	Gy	<38Gy
Bladder	V_{18Gy}	40.91±13.74	%	<50%
Rectum	Dmax	38.48±0.70	cGy	<38Gy
Rectum	V_{18Gy}	44.48±9.50	%	<50%
Femoral Head(Rt)	V_{30}	0.00±0.00	cc	<5cc

Femoral Head (Lt)	V_{30}	0.00±0.00	cc	<5cc
Penile Bulb	Dmax	38.72±0.81	cGy	<40Gy
Penile Bulb	V_{30Gy}	47.30±6.69	%	<50%

Table 2: Demonstrates the Statistical Summary of Dosimetry Metrics.

Table 2 demonstrates Dmean (Mean Dose): The average dose received by the entire PTV is approximately 37.10 Gy, with a small variation (±0.40 Gy). This indicates that, on average, the target volume receives slightly above the prescribed dose (36.25 Gy), which can be intentional to ensure coverage.

Dmax (Maximum Dose): The highest dose within the PTV is about 39.80 Gy (±1.05 Gy), reflecting dose hotspots or inhomogeneities, which are common in SBRT to boost tumor control.

D_{95}: The dose received by 95% of the PTV is approximately 35.80 Gy (±0.46 Gy). It is slightly below the prescribed dose (36.25 Gy), but still generally acceptable for ensuring adequate coverage, as it ensures most of the target gets the intended dose.

Dmin (Minimum Dose): The lowest dose within the PTV is around 32.51 Gy, indicating some dose heterogeneity but unlikely to compromise treatment efficacy.



Figure 1: Dose-volume histogram for a representative patient demonstrating target coverage (PTV) and sparing of OARs (bladder, rectum, penile bulb). The dashed line indicates the prescription dose of 36.25 Gy.



Figure 2: Pre-treatment axial CT image of the prostate showing 50% isodose line distribution.



Figure 3: Pre-treatment sagittal CT image of the prostate showing 50% isodose line distribution.



Figure 4: Pre-treatment coronal CT image of the prostate showing 50% isodose line distribution.

Figure 1 illustrates the dose-volume histogram for a representative patient, demonstrating adequate target coverage and organ sparing. Figures 2, 3, and 4 show views of the 50% dose distribution, demonstrating conformal coverage of the prostate (outlined) with rapid dose fall-off outside the target.

TABLE 3: PTV Metrics vs Prescription Dose (36.25 Gy)

Metric	Mean±SD	Interpretation	p-value
Dmean	37.10±0.40 Gy	Significantly higher	<0.001
D_{95}	35.80±0.46 Gy	Significantly lower	<0.001
Dmax	39.80±1.05 Gy	Significantly higher	<0.001

Table 3: P-values were obtained from a one-sample t-test comparing each metric to the prescribed dose of 36.25 Gy. The p-values indicate whether the mean values are significantly different from the prescribed dose.

PTV D_{95} (35.80 Gy) is below prescription (36.25 Gy) with statistical significance ($p<0.001$)[10]. But D_{95} covered 95% of the prescribed dose.Dmean/Dmax exceeds prescription ($p<0.001$), indicating hot spots (Table 3).

In SBRT, such hot spots are often intentionally created within the target to ensure adequate tumor coverage due to the highly conformal and hypofractionated nature of the treatment. These dose inhomogeneities can enhance tumor control by delivering a higher dose to the tumor core while maintaining normal tissue

constraints. However, careful planning is essential to prevent excessive doses to surrounding tissues and minimize toxicity.

TABLE 4: OAR Constraints Compliance

OAR	Metric	Constraint	Mean±SD
Bladder	Dmax	<38Gy	38.76±0.86 Gy
Rectum	Dmax	<38Gy	38.48±0.70 Gy
Bowel Bag	Dmax	<35Gy	21.55±11.2 Gy

Penile Bulb	V_{30Gy}	<50%	47.30±6.69%
Femoral Head Rt	V_{30}	<5cc	0.00±0.00cc
Femoral Head Lt	V_{30}	<5cc	0.00±0.00cc

Table 4 demonstrates the dosimetric parameters for OARs:Bladder/Rectum Dmax violate constraints ($p<0.05$)[10], Bowel Bag and Penile Bulb are within limits ($p>0.05$). Where slight exceedances of predefined dose constraints are observed for organs such as the bladder and rectum. Specifically, a slight exceedance indicates that the dose to certain organs is marginally above the established safety limits, but these levels remain close to the constraints (Table 4).

In practice, small violations may be acceptable if they do not significantly increase the risk of toxicity or adverse effects. This approach allows for flexibility in treatment planning, enabling clinicians to prioritize effective tumor coverage and overall patient safety while acknowledging minor deviations from ideal constraints.

TABLE 5: Gamma Analysis and Plan Quality Metrics for Prostate SBRT Plans

Metric	**3%/2mm Gamma Pass Rate (%)**	**2%/2mm Gamma Pass Rate (%)**	**Conformity Index (CI)**	**Gradient Index (GI)**
Mean±SD	99.94±0.08	99.67±0.23	0.905±0.18	3.08±0.16

Table 5 illustrates the dosimetric analysis demonstrated high treatment accuracy, with mean gamma pass rates of 99.94±0.08% for 3%/2mm and 99.67±0.23% for 2%/2mm criteria. The conformity index and gradient index were 0.905±0.18 and 3.08±0.16, respectively, indicating precise target coverage and sharp dose fall-off



Figure 5 offers visual insights into the balance between tumor coverage and sparing healthy organs during treatment planning. It includes four panels: (A) a box plot of PTV dose distribution; (B) the relationship between PTV V_{95} and bladder V_{18Gy}; (C) PTV V_{95} versus penile bulb dose; and (D) PTV V_{95} versus rectum V_{18Gy}. These panels collectively illustrate the various trade-offs involved in dose distribution.

Discussion

Overview of Study

This study demonstrates that prostate SBRT delivered via RapidArc on a Varian Millennium MLC system achieves highly conformal and precise dose distributions, providing target coverage consistent with or exceeding established standards.

The median PTV $_{D95\%}$ was 35.8 Gy, comparable to or slightly better than doses reported in recent clinical trials such as PACE-B, which documented an average of 34.7 ± 0.8 Gy. These results confirm that high-quality dose coverage is feasible with SBRT using RapidArc[3].

OAR parameters, including bladder Dmax (38.74 Gy), were marginally above some reported values like those from the PROFIT trial (38.5 ± 2.1 Gy). Nonetheless, these doses remained within acceptable toxicity thresholds, emphasizing that careful

planning can balance tumor coverage with OAR sparing. The slight deviations highlight the importance of strict constraint application during planning and optimization.

Treatment Planning and Delivery Efficiency

The RapidArc approach enabled treatment times of approximately 70–90 seconds per arc, significantly reducing session duration compared to traditional methods. This rapid delivery minimizes the potential for intrafractional prostate motion; however, without real-time tracking systems, some residual uncertainties may persist. To mitigate this, daily CBCT imaging was performed immediately befor each arc to verify and correct patient positioning and prostate localization.

Specifically, CBCT scans acquired before each arc allowed precise alignment of the prostate relative to the planning CT. This intra-fraction imaging protocol facilitated real-time verification of treatment setup, ensuring accurate dose delivery during each arc. Although continuous intra-fraction motion tracking was not employed, this approach effectively minimized positional errors between arcs and maintained high dosimetric accuracy.

Our dosimetric verification confirmed the consistent agreement between planned and delivered doses, underscoring the mechanical and dosimetric stability of the system and the effectiveness of the image-guided setup. The advanced inverse planning algorithms tailored for RapidArc enabled the generation of plans that met all clinical criteria, demonstrating the technique's capacity for high-quality, conformal treatment delivery efficiently.

Comparison with Literature and Clinical Implications

Our dosimetric outcomes align well with findings from recent SBRT studies. For example, the PACE-B trial reported a prostate $D_{95\%}$ of approximately 34.7 Gy, similar to our results, confirming the adequacy of target coverage[1,3]. The slightly higher bladder Dmax in our cohort suggests that further refinement of planning constraints could enhance OAR sparing.

The combination of rapid treatment times and intra-fraction CBCT imaging before each arc effectively reduces setup uncertainties and potential prostate motion during treatment. This approach allows for immediate verification and correction, ensuring high precision in dose delivery without the need for continuous intra-fraction tracking devices[9].

Although some plans exhibited higher doses to the bladder, ongoing optimization of planning constraints such as tighter OAR limits and adaptive planning may further improve normal tissue sparing without compromising tumor coverage.

Leaf Speed Distribution



Figure 6: Distribution of MLC leaf speed data during treatment delivery, demonstrating variations in leaf velocity required for dose modulation and conformity.

The histogram shows that the majority of MLC leaves remained stationary or moved very slowly during treatment, with most speeds clustered near zero. There are relatively few instances of higher leaf speeds, and most are well below the maximum threshold of 3 cm/s marked by the red dashed line(Figure 6). Rapid leaf movements or complex modulation would typically show a broader distribution with more high-speed movements, which doesn't seem to be the case here.

Since most leaf speeds are below the threshold, it indicates that the plan was delivered with controlled leaf motions that reduce the risk of inaccuracies. The minimal high-speed movements suggest precise targeting without abrupt leaf motions, contributing to accurate dose delivery[5]. The Plan appears to have been executed smoothly with controlled leaf movements, indicating a well-optimized plan that likely emphasizes precision and safety.

Mean leaf speed: 0.59 cm/s

Max leaf speed: 3.00 cm/s

Comparison of MLC Leaf Motion Relative to Isocenter(Center of PTV)

In this study, we performed an in-depth analysis of multi-leaf collimator (MLC) leaf dynamics during radiotherapy delivery, focusing on the positional behavior of specific leaf groups relative to the isocenter, which was positioned at the center of the PTV (Planning Target Volume). We compared the movement patterns of the offset leaves (leaves 1 to 10) and the leaves located adjacent to the isocenter (leaves 30 to 40).

Offset Leaves (1-10)



Figure 7: MLC leaf positions (leaves 1–10) over time during treatment, illustrating dynamic movements to shape the beam.

As illustrated in Figure 7, these leaves, positioned away from the isocenter, showed relatively stable positions throughout the treatment duration. Leaf 8 and 9 remained nearly stationary, indicating minimal modulation, likely serving as fixed field boundaries. In contrast, leaf 10 demonstrated significant and rapid positional shifts after approximately 60 seconds, suggesting active modulation to accommodate treatment requirements or compensate for patient movement.

Leaves Adjacent to Isocenter (30-40)



Figure 8 depicts the movement patterns of the leaves located near the isocenter, which was placed at the center of the PTV. These leaves exhibited continuous fluctuations and abrupt positional changes over the course of the treatment session. This dynamic behavior reflects the necessity for precise modulation near the target to achieve conformal dose delivery while sparing surrounding healthy tissue.

Figure 8: MLC leaf positions (leaves 30–40) over time, showing adjustments in outer bank leaves for beam shaping and dose control.

Study Strengths and Generalisability

This study is strengthened by its detailed dosimetric evaluation incorporating not only PTV and OAR metrics but also advanced parameters such as MLC leaf speed and dynamic leaf positioning, providing a comprehensive insight into treatment delivery accuracy. Additionally, the use of intra-fraction CBCT before each arc enhanced treatment precision without requiring continuous motion tracking, making the workflow efficient and clinically practical.

Clinical Significance

Our results support that SBRT delivered via RapidArc, with intra-fraction Cone Beam Computed Tomography(CBCT) imaging before each arc, offers a practical and effective treatment option for prostate cancer. This approach achieves high-quality conformal dose distributions with efficient treatment times and robust verification of prostate positioning during each arc, all without the need for real-time motion tracking devices.

This protocol minimizes treatment duration and setup uncertainties, enhancing patient comfort and treatment accuracy. The intra-fraction CBCT verification before each arc ensures precise targeting and dose delivery, making this a reliable and accessible strategy in routine clinical practice.

In conclusion, SBRT using RapidArc combined with intra-fraction CBCT imaging before each arc provides a promising approach for prostate radiotherapy, balancing precision, efficiency, and safety. Future advancements in intra-fraction motion management will further refine this modality and potentially improve clinical outcomes.

Conclusions

This study highlights the potential of SBRT using advanced techniques like RapidArc for the precise and efficient treatment of prostate cancer. Daily intra-fraction imaging, such as CBCT before each arc, enhances treatment accuracy by effectively managing organ motion, ensuring optimal target coverage while minimizing dose to surrounding healthy tissues. The implementation of high-dose, hypofractionated schedules-such as 36.25 Gy delivered in five fractions-demonstrates promising dosimetric feasibility and safety, with excellent target coverage. However, attention must be given to bladder and rectum dose constraints to further reduce toxicity risks. The use of RapidArc significantly reduces treatment time and improves plan conformity, making SBRT a practical and patient-friendly option. These advancements support the ongoing development of personalized, high-precision radiotherapy protocols that balance efficacy with safety. Future research should focus on refining motion management and dose constraints to optimize clinical outcomes and minimize adverse effects in prostate SBRT.

Acknowledgements: none

Funding: none

Conflict of interest: none declared

Data Availability Statement:

The data that support the findings of this study are available from the corresponding author upon reasonable request.

459 **References**

460 1.D. Dearnaley.: Conventional versus hypofractionated high-dose intensity-
461 modulated radiotherapy for prostate cancer: 5-year outcomes of the randomized,
462 non-inferiority, phase 3 CHHiP trial," The. Lancet Oncology, vol. 17, no. 8, pp. 1047-
463 1060, Aug. 2016,

464 2. Freeman DE, King CR: Stereotactic body radiotherapy for low-risk prostate
465 cancer. JAMA. 2018, 319:437.

466 3.E. Wieslander, V. Jóhannesson, P. Nilsson: Ultrahypofractionated Radiation
467 Therapy for Prostate Cancer Including Seminal Vesicles in the Target Volume: A
468 Treatment-planning Study Based on the HYPO-RT-PC Fractionation Schedule,.
469 Advances in Radiation Oncology, vol. 9, no. 7, p. 101531, Jul. 2024,

470 4.K. Wang: Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity
471 and Dose Response, . International Journal of Radiation Oncology*Biology*Physics,
472 vol. 110, no. 1, pp. 237-248, May. 2021

473 5. Chen, J., Cui, W., Fu, Q.: Influence of maximum MLC leaf speed on the quality of
474 volumetric modulated arc therapy plans. Journal of Applied Clinical Medical Physics.
475 21:37-47.

476 6. Sun H, Wang N, Huang G, Liu X: Dosimetric comparison of fixed field dynamic
477 IMRT and VMAT techniques in simultaneous integrated boost radiotherapy of
478 prostate cancer. Medicine (Baltimore. 2023, 102:32063).

479 7. Pandit-Taskar N, Iravani A, Lee D, Jacene H, Pryma D, Hope T: Dosimetry in
480 Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in
481 Current Practice. J Nucl Med.

482 8. Tali TA, Khan MR: A Comparative Dosimetric Evaluation of Intensity-Modulated
483 Radiation Therapy (IMRT) and Three-Dimensional Conformal Radiotherapy
484 (3DCRT) for Prostate Cancer with Testicular Shielding. Asian Pac J Cancer Care.
485 2024, 9:295-301.

486 9. Jmour, O., Benna, M., Champagnol: CBCT evaluation of inter- and intra-fraction
487 motions during prostate stereotactic body radiotherapy: A technical note. Radiation
488 Oncology. 15:84-10.

489 10. Catton CN, Lukka H, Gu C-S, et al.: Randomized Trial of a Hypofractionated
490 Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol.
491 2017, 35:1884-1890.